The American College of Rheumatology’s two-part guidelines stress the need for treating to target, more aggressive management, and therapy
Search results for: corticosteroids
Drug Updates: Lorcaserin, Acetaminophen, and More
information on new approvals and medication safety
Inflammatory Myopathies in Children
Treatment options and recent research for juvenile dermatomyositis.
Minerals, Mud, Martinis, and Methylprednisone
How the practice of rheumatology differs in America and Europe.
Systemic Juvenile Idiopathic Arthritis
Changing treatment paradigms in the biologic era
New Osteoarthritis Recommendations and Classification Criteria for Sjögren’s Syndrome and Polymyalgia Rheumatica
The ACR has published three documents intended to provide clarity and consensus on management of osteoarthritis, classification criteria for Sjögren’s syndrome, and classification criteria for polymyalgia rheumatica. The documents, which represent the most current clinical evidence, research, and expert panel input and review, can help inform clinical practice and provide clearer target populations for future research.
Dermatology Case: History of ANCA–Associated Vasculitis, Fever, Rash
A 66-year-old woman with a history of antineutrophil cytoplasmic antibody (ANCA)–associated vasculitis presents with two days of fever and rash.
Dermatology Case Answer: History of ANCA–Associated Vasculitis, Fever, Rash
A 66-year-old woman with a history of antineutrophil cytoplasmic antibody (ANCA)–associated vasculitis presents with two days of fever and rash.
Treatment Patterns and Trends for Spondylarthropathies
Methotrexate is a commonly used disease-modifying antirheumatic drug (DMARD) for treating patients with psoriatic arthritis (PsA). However, is it truly as effective as many think it is? That’s the question raised during the session “Spondylarthropathies: Recent Insights,” which took place at the 2011 ACR/ARHP Annual Scientific Meeting in November.
The Mystery of IVIg
Although initially given as replacement therapy for patients with primary and secondary immunodeficiency states, intravenous immunoglobulin (IVIg) has proven to be effective in the treatment of various autoimmune and inflammatory disorders. This success has led to a dramatic increase in the use of IVIg, with its use as an antiinflammatory agent now vastly surpassing its use in the treatment of immunodeficiencies. Even so, the basis for the antiinflammatory activity of IVIg remains unclear.
- « Previous Page
- 1
- …
- 34
- 35
- 36
- 37
- 38
- …
- 42
- Next Page »